Skip to main content
Publications

Securities Class Actions in the Life Sciences Sector

Spring 2025
Authors
Sara B. BrodySarah A. HemmendingerFrancesca E. BrodyRobin E. Wechkin

Sidley is pleased to present its annual review addressing developments in securities class actions brought against life sciences companies in 2024.

In this publication, we begin with an overview and analysis of trends in federal district court and appellate decisions in these cases. We then provide summaries of the 49 decisions surveyed. Finally, we catalog the new securities class action complaints filed against life sciences companies in 2024.

Click here to download the PDF.
Click here to view a two-page summary.
Click here to order hard copies. Limited supply available.

Knowledge Management Lawyer Zarine Alam also contributed to the 2024 annual report.

Contacts

Brody, Sara B.
Partner
Hemmendinger, Sarah A.
Partner
Brody, Francesca E.
Partner
Wechkin, Robin E.
Counsel
Seattle
+1 415 439 1799

Capabilities

Suggested News & Insights

U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 12, 2025
GoodLifeSci
Sidley Represents Immunovant in US$550 Million OfferingDecember 12, 2025
Announcements
BIOSECURE Act Included in the FY2026 National Defense Authorization ActDecember 12, 2025
Government Strategies Update
Sidley Ranked in Chambers Asia-Pacific 2026December 11, 2025
Accolades
U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 11, 2025
Global Life Sciences Update
What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025
GoodLifeSci